insights_auto
Why is NL0 down 7.67%?
Dive Deeperchevron_right
NL0:FRA
Grail Inc
€112.55
arrow_downward
-7.67%(-9.35) 1D
Oct 16, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NL0...
Open
€119.35
High
€119.35
Low
€112.55
Mkt. cap
5.26B
Avg. vol.
29.00
Volume
57.00
52-wk high
€142.70
52-wk low
€34.00
No. of employees
910
Open
€119.35
High
€119.35
Low
€112.55
Mkt. cap
5.26B
Avg. vol.
29.00
Volume
57.00
52-wk high
€142.70
52-wk low
€34.00
No. of employees
910
News stories
From web sources and news partners
Investing.com Nigeria
·
3 hours ago
Form 4 Grail Inc: Steven Mizell (Director) For: 15 October By Investing.com
Investing.com Nigeria
·
3 hours ago
Grail CEO Joshua Ofman sells $2.74m in company stock By Investing.com
Stock Titan
·
10 hours ago
GRAIL (GRAL) director Gregory L. Summe receives 237 stock units instead of $32.1K in cash fees.
Stock Titan
·
1 day ago
A director proposes selling 5,000 GRAIL (GRAL) shares around October 15, 2026.
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com